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MaOBJECTIVES This study was designed to analyze the prevalence and potential genetic basis of cancer and heart failure
in peripartum cardiomyopathy (PPCM).
BACKGROUND PPCM manifests as heart failure late in pregnancy or postpartum in women without previous heart
disease.
METHODS Clinical history and cancer prevalence were evaluated in a cohort of 236 PPCM patients from Germany and
Sweden. Exome sequencing assessed variants in 133 genes associated with cancer predisposition syndromes (CPS) and in
115 genes associated with dilated/hypertrophic cardiomyopathy (DCM/HCM) in 14 PPCM patients with a history of cancer,
and in 6 PPCM patients without a history of cancer.
RESULTS The prevalence of cancer was 16-fold higher (8.9%, 21 of 236 patients) in PPCM patients compared to age-
matched women (German cancer registry, Robert-Koch-Institute: 0.59%; p < 0.001). Cancer before PPCM occurred in 12
of 21 patients of whom 11 obtained cardiotoxic cancer therapies. Of those, 17% fully recovered cardiac function by
7  2 months of follow-up compared to 55% of PPCM patients without cancer (p ¼ 0.015). Cancer occurred after PPCM in
10 of 21 patients; 80% had left ventricular ejection fraction of $50% after cancer therapy. Whole-exome sequencing in
14 PPCM patients with cancer revealed that 43% (6 of 14 patients) carried likely pathogenic (Class IV) or pathogenic
(Class V) gene variants associated with DCM/HCM in CPT2, DSP, MYH7, TTN, and/or with CPS in ATM, ERCC5, NBN,
RECQL4, and SLX4. All CPS variants affected DNA damage response genes.
CONCLUSIONS Cardiotoxic cancer therapy before PPCM is associated with delayed full recovery. The high cancer
prevalence in PPCM is linked to likely pathogenic/pathogenic gene variants associated with DCM/HCM and/or CPS/DNA
damage response–related cancer risk. This may warrant genetic testing and screening for heart failure in pregnant women
with a cancer history and screening for cancer in PPCM patients. (J Am Coll Cardiol CardioOnc 2019;1:196–205)
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AB BR E V I A T I O N
AND ACRONYM S
ATM = ataxia telangiectasia
mutated
BMBF = Bundesministerium für
Bildung und Forschung
BRCA1 = breast cancer 1
CPS = cancer predisposition
syndrome
DCM = dilated cardiomyopathy
DDR = DNA damage response
DFG = Deutsche
Forschungsgesellschaft
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197P eripartum cardiomyopathy (PPCM) is a life-threatening heart disease which emerges inthe last month of pregnancy or in the first
months after delivery in previously heart-healthy
women. PPCM is defined as an idiopathic cardiomy-
opathy with left ventricular ejection fraction (LVEF)
<45% with no other cause for heart failure found
(1,2). The mechanisms leading to PPCM remain
incompletely understood. A set of risk factors
including pregnancy-associated hypertensive disor-
ders, multiparity, higher maternal age, smoking,
malnutrition, and infection are considered to play
crucial roles (1,3).SEE PAGE 206 ERCC5 = excision repair cross-
complementing rodent repair
deficiency
FANCA = Fanconi anemia,
complementation group
FKRP = fukutin-related protein
HCM = hypertrophic
cardiomyopathy
HTX = heart transplantation
LVAD = left ventricular assist
device











VUS = variants of unknown
ficancePrevious work has examined links between the
cardiotoxicity of cancer treatment and heart failure
surrounding pregnancy and found that women who
experienced cardiotoxicity had a higher risk for
developing heart failure in pregnancy, whereas the
risk is less substantial for women who do not expe-
rience short-term cardiotoxicity (4). However, regis-
try data and case studies also suggest an association
between cardiotoxic cancer therapies and PPCM even
in patients who do not display left ventricular (LV)
dysfunction immediately after cancer treatment (5,6).
Recent data also suggest that heart failure may pro-
mote tumor growth, providing additional mechanistic
evidence for an overlap between these 2 disease
states (7). Thus, we hypothesized that there are
important potential interactions between cancer dis-
ease and pregnancy-associated heart failure, partic-
ularly in PPCM, where the disease-inducing and
pathophysiologic basis remain largely unknown
(1,8–11). In the present study, we analyzed data from
236 PPCM patients from a German and a Swedish
PPCM cohort to determine the incidence of cancer
and changes in cardiac function over time. We per-
formed exome sequencing in 133 genes associated
with cancer predisposition syndromes (CPSs) and 115
genes associated with dilated/hypertrophic cardio-
myopathy (DCM/HCM) in 20 participants from this
well-phenotyped cohort.
METHODS
STUDY POPULATION. This study included 211 pa-
tients from the German PPCM registry (6) and 25
patients from a Swedish cohort for whom full med-
ical history was available at the time of PPCM diag-
nosis. All 236 patients were enrolled into the
registries between 2004 and 2018. Both studies were
approved by the respective local ethics committees
and all patients provided appropriate writteninformed consent. All patients met the
diagnostic criteria of PPCM including the
absence of documented previous heart dis-
ease and LVEF <45% (2).
Detailed information regarding their PPCM
diagnosis was provided by all patients, either
by medical records or by phone interview.
Detailed clinical history, such as onset of
symptoms and signs during first presenta-
tion, New York Heart Association functional
class, electrocardiogram (ECG), echocardio-
grams, family history, diseases during preg-
nancy, and the mode of delivery were
obtained from the patients, the referring
physician, and by examining the obstetric
and medical records. Furthermore, patients
were divided into subgroups depending on
their cardiac status at 7  2 months of follow-
up: no recovery (LVEF #35%; heart transplant
[HTX]; left ventricular assist device [LV assist
device implantation or death); partial recov-
ery (LVEF >35% to 49%); and full recovery
(LVEF $50%).
In 207 patients, information regarding the
occurrence of cancer was also provided.
Cancer prevalence in the cohort was
compared to the 10-year prevalence in age-
matched women (from 0 to 49 years of age)
in the German cancer registry of the Robert-
Koch-Institute (RKI) (12). The RKI registry is
based on data of the German epidemiologic
registries where all newly diagnosed cancer
diseases are reported and the incidence is
calculated.
EXOME SEQUENCING AND VARIANTCLASSIFICATION. Exome sequencing was performed
in 14 PPCM patients with a history of cancer, and in 6
PPCM patients without a history of cancer where
appropriate blood samples were available. DNA was
extracted from whole blood samples. DNA enrichment
and library preparation was performed using the xGen
Exome Research Panel (Integrated DNA Technologies,
Inc., Coralville, Iowa). Sequencing was performed on
an Illumina NextSeq 500 using the NextSeq 500/550
High Output v2 kit (Illumina, San Diego, California).
Alignment to the reference genome build (GRCh37)
was performed using megSAP, version 0.1-710-
g52d2b0c (Institute of Medical Genetics and Applied
Genomics, University of Tübingen, Tübingen,
Germany). Variant prioritization and visualization was
performed with GSvar, version 2018_04, Integrated
Genomics Viewer (13), version 2.4.14 and with Alamut
visual, version 2.11 (Interactive Biosoftware, Rouen,
signi











Age at index, yrs 34  5 (n ¼ 236) 34  5 (n ¼ 215) 34  5 (n ¼ 21) 33  6 (n ¼ 12)
Parity SSP 1 (0–8) (n ¼ 223) 1 (0–8) (n ¼ 204) 1 (1–5) (n ¼ 19) 1 (1–3) (n ¼ 10)
Twin pregnancy 17 (35/212) 16 (31/193) 21 (4/19) 30 (3/10)
Caesarean section 70 (142/202) 70 (128/182) 70 (14/20) 82 (9/11)
Pregnancy-induced hypertensive disorders 39 (88/227) 40 (83/206) 24 (5/21) 17 (2/12)
Baseline LVEF, % 28  10 (n ¼ 236) 28  10 (n ¼ 215) 29  9 (n ¼ 21) 31  10 (n ¼ 12)
Follow-up LVEF, % 50  11 (n ¼ 165) 51  11 (n ¼ 145) 46  10 (n ¼ 20)* 43  7 (n ¼ 12)†
Beta-blocker, % 91 (207/228) 91 (188/207) 90 (19/21) 92 (11/12)
ACE inhibitor, ARB, % 95 (214/226) 95 (196/206) 90 (18/20) 91 (10/11)
Bromocriptine, % 78 (175/224) 79 (161/203) 67 (14/21) 75 (9/12)
Severe heart failure during follow-up, % 15 (27/175) 14 (21/154) 29 (6/21) 25 (3/12)
HTX/LVAD/death during follow-up, % 6 (10/175) 6 (9/154) 5 (1/21) 0 (0/12)
Full recovery at follow-up, % 53 (92/175) 55 (84/154) 38 (8/21) 17 (2/12)‡
Values are mean  SD, mean (range), or % (n/N). The exact number of datasets analyzed for each parameter is provided in parentheses after each of the values. Baseline refers to time of PPCM diagnosis.
Follow-up after PPCM in Table 1 was 7  2 months with regard to follow-up LVEF. Severe heart failure at follow-up is defined as LVEF #35%, HTX, LVAD, or death during follow-up. Full-recovery at follow-
up is defined as LVEF $50%. None of these patients experienced an abortion, miscarriage, or still birth. Comparison between the 2 groups (PPCM with cancer vs. PPCM without cancer) was performed using
the Student’s t-test for Gaussian distributed data and the Mann-Whitney U test where at least 1 column was not normally distributed. Categorical variables are presented as frequencies (proportions) and
compared using Fisher exact tests. *p < 0.05 PPCM patients with cancer vs. PPCM patients without cancer; †p < 0.01 and ‡p < 0.05 PPCM patients with cancer prior PPCM vs. PPCM patients without cancer.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; HTX ¼ heart transplantation; LVAD ¼ left ventricular assist device; LVEF ¼ left ventricular ejection fraction;
PPCM ¼ peripartum cardiomyopathy.
Pfeffer et al. J A C C : C A R D I O O N C O L O G Y , V O L . 1 , N O . 2 , 2 0 1 9
Increased Cancer Prevalence in PPCM D E C E M B E R 2 0 1 9 : 1 9 6 – 2 0 5
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criteria proposed by the American College of Medical
Genetics and Genomics (ACMG) (14), and 248 genes
were analyzed per patient. Genes associated with DCM
were selected using the human phenotype ontology
database (15) term “dilated cardiomyopathy”
(HP:0001644; 115 genes); genes associated with DNA
damage response (DDR) and general CPSs were
composed of all genes listed in a benchmark study
regarding cancer predisposition gene testing in adult
patients (16) (Supplemental Tables 1 and 2). Only ge-
netic variants which were classified as ACMG class III
(variants of unknown significance) or likely patho-
genic/pathogenic (ACMG class IV/V), thus inducing
nonsense, missense, or frameshift mutations,
were considered.
STATISTICAL ANALYSIS. Statistical analysis of the
clinical data was performed using GraphPad Prism
version 5.0a for Mac OS X (GraphPad Software, San
Diego, California). Normal distribution was tested
using the D’Agostino normality test. Continuous data
were expressed as mean  SD or median (range), ac-
cording to normality of distribution. Comparison be-
tween the groups was performed using Student’s
t-test for Gaussian distributed data and the Mann-
Whitney U test where at least 1 column was not nor-
mally distributed. Categorical variables are presented
as frequencies (proportions) and compared using
Fisher exact tests. The incidences of cancer in PPCM
patients and the RKI registry were compared using
2-tailed chi-square test and odds ratios (ORs).Distribution in the 3 different subgroups depending
on the cardiac status was compared using the chi-
square test. All p values are 2-sided, and a p value
of <0.05 was considered to be significant.
RESULTS
HIGH CANCER PREVALENCE IN PPCM PATIENTS,
CLINICAL CHARACTERISTICS, AND OUTCOME. A
total of 236 patients from German and Swedish PPCM
cohorts (211 German and 25 Swedish patients) with a
confirmed PPCM diagnosis and clinical history of
either a confirmed presence or absence of a cancer
diagnosis were included in the study. As both col-
lectives were comparable regarding their character-
istics and clinical data at baseline and over 7 
2 months follow-up, the data were pooled (Table 1). A
history of cancer before PPCM or a cancer diagnosis
after PPCM was identified in 21 of 236 (8.9%) PPCM
patients over a median follow-up time of 33 months
(range 5 months to 19 years). The cancer prevalence
was 8.1% (17 of 211 patients) in the German cohort and
16% (4 of 25 patients) in the Swedish cohort. In
comparison, the RKI registry (12) displayed a cancer
prevalence of 0.59% in German women aged 0 to 49
years, indicating a 16-fold higher risk of cancer in this
PPCM cohort compared to age-matched women
without PPCM (OR: 16.4; 95% confidence interval [CI]:
10.5 to 25.7; p < 0.001). There were 23 cancer di-
agnoses in 21 patients. One patient (Patient #11)
developed 2 different forms of cancer before PPCM
and 1 patient (Patient #9) developed cancer both
TABLE 2 Age at Tumor and PPCM, Baseline and Follow-Up LVEF, Anticancer Treatment, and Genetic Variants in PPCM Patients With Cancer Before PPCM















02 Breast cancer 37 40 35 46 Antihormone therapy, surgery, radiation CPT2 (P)




04 Non-Hodgkin lymphoma 20 24 30 30 Chemotherapy (doxorubicin), radiation TTN (VUS)
05 Acute myeloid leukemia 13 34 45 45 Chemotherapy (cytarabine, daunorubicin,
doxorubicin, vincristine), radiation
MYBPC3 (VUS)
06 Osteosarcoma 10 23 27 47 Chemotherapy (cisplatin, methotrexate) MYH7 (LP)
SLX4 (LP)
07 Osteosarcoma 11 35 45 47 Chemotherapy unknown composition 2 variants in RECQL4 (LP/LP)
2 variants in FANCA (VUS/VUS)
08 Melanoma 33 39 15 33 Surgery none
09 Hodgkin lymphoma 17 36 40 45 Radiation TTN (P)
ATM (P)
ERCC5 (P)
10 Non-Hodgkin lymphoma 35 40 32 54 Chemotherapy (adriamycin, cyclophosphamide,
rituximab, vincristine)
TTN (VUS)
11 Acute lymphatic leukemia
þ melanoma
4 31 20 36 Chemotherapy (daunorubicin, doxorubicin) TXNRD2 (VUS) ATM (VUS)




Cardiac function at the time of diagnosis (baseline) and follow-up after PPCM in PPCM patients with malignancies before PPCM. Variants identified by exome sequencing are presented with their corre-
sponding American College of Medical Genetics and Genomics class. All LP/P variants are in bold.
ATM ¼ TM serine/threonine kinase; BRCA1 ¼ breast cancer gene 1; CPT2 ¼ carnitine-palmitoyltransferase II; DSG2 ¼ desmoplakin; ERCC5 ¼ excision repair cross-complementation group 5;
FANCA ¼ Fanconi anemia, complementation group; HTX ¼ heart transplantation; LP ¼ likely pathogenic; LVEF ¼ left ventricular ejection fraction; MYBPC3 ¼ cardiac myosin binding protein C;
MYH7 ¼ myosin heavy chain 7; P ¼ pathogenic; PPCM ¼ peripartum cardiomyopathy; RECQL4 ¼ ATP-dependent DNA helicase Q4; SLX4 ¼ structure-specific endonuclease subunit SLX4; TTN ¼ titin;
TXNRD2 ¼ thioredoxin reductase 2; VUS ¼ variant of unknown significance.
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199before (Hodgkin’s lymphoma) and after PPCM (breast
cancer) (Tables 2 and 3).
OUTCOME OF PPCM PATIENTS WITH CANCER
BEFORE PPCM. Cancer occurred in 5.1% (12 of 236
patients) of patients before their diagnosis of PPCM
(age range at PPCM diagnosis: 19 to 45 years) which is
9-fold higher compared to age-matched females in
the RKI registry (women aged 0 to 49 years had a
cancer risk of 0.59%; OR: 9.0; 95% CI: 5.0 to 16.1). Of
the patients with cancer before PPCM, 92% (11 of 12
patients) had undergone cancer therapy and/or radi-
ation (Tables 1 and 2). To understand whether anti-
cancer treatment may have induced heart failure
before pregnancy, all 11 cases of patients treated with
drug therapy and/or radiation were re-evaluated
regarding the differential diagnosis of cardiomyopa-
thy induced by cardiotoxic cancer therapy and signs
of heart failure before pregnancy. None of 11 patients
reported any signs of heart failure after cancer ther-
apy and prior to pregnancy. At baseline, all PPCM
patients with and without cancer displayed a similar
LVEF, but at 7  2 months follow-up, the mean LVEF
was significantly lower in all PPCM patients with a
history of cancer (Table 1). In addition, fewer patientswith a cancer diagnosis before PPCM displayed full
cardiac recovery at follow-up compared with patients
with no cancer history (Figure 1, Table 1).
PREVALENCE AND OUTCOME OF PPCM PATIENTS
WITH A CANCER DIAGNOSIS AFTER PPCM. In 207
PPCM patients (age range 20 to 50 years), clinical
follow-up data after diagnosis were available for a
median of 33 months (range 5 months to 19 years). Of
those, 4.83% (10 of 207) patients developed cancer
after PPCM, with 1 patient having had a different
cancer diagnosis before PPCM (Tables 2 and 3).
Compared with the cancer prevalence in women of
the same age group (RKI women aged 0 to 49 years:
0.59%), PPCM patients had a 9-fold higher risk for
cancer after PPCM (OR: 8.5; 95% CI: 4.5 to 16.1). For all
patients with cancer after PPCM, LVEF at the time of
PPCM diagnosis, after cancer diagnosis, and after
cancer therapy were available (Table 3). One patient
with a prolactinoma diagnosed shortly after PPCM
diagnosis did not obtain the recommended anticancer
treatment with a prolactin blocker and required HTX
3 months after PPCM diagnosis (Table 3). A second
patient diagnosed with prolactinoma was treated
with the prolactin blocker bromocriptine and
TABLE 3 Age at Tumor Diagnosis and PPCM, Baseline LVEF at PPCM Diagnosis, LVEF After Anticancer Treatment, and Genetic Variants in
PPCM Patients With Cancer After PPCM








Cancer Therapy Anticancer Therapy
Genetic Variant
(P/LP/VUS)
09 Breast cancer 48 36 40 46 Antihormone therapy, surgery, radiation TTN (P)
ATM (P)
ERCC5 (P)








15 Colorectal cancer 33 31 30 60 Surgery Not performed
16 Prolactinoma 30 30 12 HTX No antitumor therapy Not performed
17 Ovarian cancer 36 31 29 55 Surgery RYR1 (VUS)
18 Microprolactinoma 31 31 30 58 No antitumor therapy but bromocriptine Not performed
19 Cervical cancer 45 39 30 50 Surgery Not performed
20 Breast cancer 51 39 22 50 Chemotherapy: tamoxifen; radiation; surgery Not performed
21 Cervical cancer 41 40 32 55 Surgery Not performed
Cardiac function at the time of diagnosis and after cancer therapy in PPCM patients with malignancies after PPCM. PPCM patient 9 had Hodgkin lymphoma before PPCM and
breast cancer after PPCM (see Table 2). Variants identified by exome sequencing are presented with their corresponding American College of Medical Genetics and Genomics
class. All LP/P variants are in bold.
ATM ¼ TM serine/threonine kinase; ERCC5 ¼ excision repair cross-complementation group 5; HTX ¼ heart transplantation; LP ¼ likely pathogenic; LVEF ¼ left ventricular
ejection fraction; NBN ¼ nibrin; P ¼ pathogenic; POLD1 ¼ polymerase delta 1; PPCM ¼ peripartum cardiomyopathy; RYR1 ¼ ryanodine receptor 1; TTN ¼ titin; VUS ¼ variant of
unknown significance.
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200recovered (Table 3). A patient with Hodgkin lym-
phoma treated with radiation therapy before PPCM
and also treated for breast cancer with antihormone
therapy, radiation, and surgery after PPCM was in
moderate heart failure after the second cancer and
corresponding treatment (Tables 2 and 3). The 7
remaining patients displayed normal LV function af-
ter cancer diagnosis and treatment; none developed
acute heart failure while undergoing anticancer
therapy after PPCM, and none received
anthracycline-based chemotherapies (Table 3).FIGURE 1 Cardiac Status at 7  2 Months Follow-Up in PPCM Patien


















Cardiac status at 7  2 months follow-up in PPCM patients stratified ac
7  2 months follow-up in PPCM patients without cancer and with cance
before PPCM (B). Red column ¼ nonrecovery (LVEF #35%, HTX, LVAD
>35% to 49%); green column ¼ full recovery (LVEF $50%). The p val
transplantation; LVAD ¼ left ventricular assist device; LVEF ¼ left ventrEXOME SEQUENCING REVEALS THE PRESENCE OF GENE
VARIANTS ASSOCIATED WITH CARDIOMYOPATHY AND A
HIGHER CANCER RISK IN PPCM PATIENTS WITH CANCER.
Exome sequencing was performed in a subset of 14
PPCM patients: 10 had developed cancer before and
3 after the onset of PPCM, and 1 patient developed
cancer before and after PPCM (Tables 2 and 3). In 13
of 14 patients (93%), either pathogenic (P, class V),
likely pathogenic (LP, class IV) variants, and/or
variants of unknown significance (VUS, class III)
associated with DCM/HCM and/or CPS werets Stratified According to Cancer Diagnosis


















cording to cancer diagnosis. Comparison of cardiac status at
r before and after PPCM (A), and in PPCM patients who had cancer
implantation, or death); yellow column ¼ partial recovery (LVEF
ues were calculated using chi square test; *p < 0.05. HTX ¼ heart
icular ejection fraction; PPCM ¼ peripartum cardiomyopathy.
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201detected. Forty-three percent (6 of 14 patients) car-
ried only LP and P variants in DCM/HCM and/or CPS
(Table 2 and 3). All gene variants were either
missense, frameshift, or nonsense mutations; an
overview of all variant details including full gene
names, sequence information, and variant frequency
in the general population according to the gnomAD
database (17) is presented in Supplemental Table 3.
In 11 patients, VUS and P/LP variants associated with
cardiomyopathy were found in 8 genes (CPT2, DSG2,
DSP, MYBPC3, MYH7, RYR1, TTN, and TXNRD2).
Five patients carried LP/P variants in CPT2, DSP,
MYH7, or TTN and in 7 patients, 7 VUS were iden-
tified in DSG2, MYPBC3, RYR1, TTN, and TXNRD2
(Tables 2 and 3). One patient with cancer before
PPCM carried an LP/P in DSP and a VUS variant in
DSG2 (Table 2).
In 7 of 14 patients, VUS and LP/P gene variants
associated with CPS were found in 8 different genes
(ATM, BRCA1, ERCC5, FANCA, NBN, POLD1, RECQL4,
and SLX4), with all affected genes involved in DDR
(18–22). Four of 14 patients carried LP/P variants in
ATM, ERCC5, NBN, RECQL4, and SLX4 (Tables 2 and 3).
One patient was compound heterozygous for 2
different LP variants in RECQL4 and also for 2 different
rare FANCA VUS (Table 2). Five patients carried VUS or
LP/P gene variants associated with DCM and CPS.
Within this group, 3 patients were identified with only
LP/P variants in DCM/HCM and in CPS genes, including
the patient with cancer before and after PPCM (only P
gene variants in TTN, ATM, and ERCC5), 1 patient
with cancer before PPCM (LP gene variants in MYH7
and in SLX4), and 1 patient with cancer after PPCM
(LP gene variant in TTN and P gene variant in NBN)
(Tables 2 and 3).
PRESENCE OF GENE VARIANTS ASSOCIATED WITH
CARDIOMYOPATHY AND/OR A HIGHER CANCER
RISK IN PPCM PATIENTS WITHOUT A CANCER
DIAGNOSIS. Whole-exome sequencing in 6 PPCM
patients with no history of cancer revealed that 1
patient carried a P variant in the FKRP gene leading to
Emery Dreyfuss muscular dystrophy associated with
cardiomyopathy (23), 1 patient carried a VUS in MYH7,
and 1 patient carried a VUS in TTN and another VUS in
E-Cadherin 1 (CDH1) (Supplemental Table 4). CDH1 is
a CPS gene associated with cell-to-cell interaction
(24). No DDR-associated gene variants were detected
in these patients.
DISCUSSION
The present study reports a 16-fold higher prevalence
of early-onset cancer in PPCM patients from 2 Euro-
pean PPCM cohorts compared to the cancer risk inage-matched women without PPCM (Central
Illustration). The risk for cancer before PPCM was 9-
fold and for cancer after PPCM was also 9-fold
higher compared to age-matched women without
PPCM. It has been reported that pregnancy before the
age of 30 years decreases the risk for breast cancer
(25), whereas pregnancy after the age of 35 years may
increase slightly (by 0.041%) the risk for breast can-
cer in the first 5 postpartum years (26). Adding the
slightly increased cancer risk after pregnancy in older
women to the general risk (0.59%) of women age 0 to
49 years, the risk of cancer for older postpartum
women is estimated to be 0.63%. The average age of
patients with cancer after PPCM was 35 years at the
time of PPCM diagnosis, suggesting that this group
may have a slightly increased cancer risk compared
to women without late pregnancies. However, as
4.83% of PPCM patients developed cancer after
PPCM, the risk for cancer when calculated on the
0.63% cancer risk for women with pregnancies after
the age of 35 years in this subgroup is still 8-fold
higher compared to age-matched postpartum
women without PPCM. Taken together, PPCM pa-
tients in the German and Swedish cohorts have a
markedly increased risk for cancer both before and
after PPCM compared to the cancer risk of age-
matched women without PPCM.
Cardiac function at the time of PPCM diagnosis
was comparable across the entire cohort, but the
rate of full recovery was lower in PPCM patients
with cancer before PPCM compared with PPCM pa-
tients with no cancer history before PPCM. In pa-
tients with cancer before PPCM, cancer was detected
mostly during childhood or adolescence with the
majority undergoing anticancer treatments including
potentially cardiotoxic drug therapy (anthracyclines,
other cytotoxic antibiotics, alkylating agents, anti-
metabolites, or antimicrotubule agents) and/or ra-
diation. Cancer therapy–induced cardiotoxicity can
manifest both short-term and later in life (27–30).
None of the PPCM patients with cancer before PPCM
reported short-term or long-term cardiotoxic effects
in response to anticancer treatment, suggesting that
pregnancy may have induced PPCM as a form of late
cardiotoxicity.
A recent study has shown that patients with rare
gene variants associated with DCM/HCM have a
higher risk for cardiomyopathies induced by cancer
therapy (31). In our cohort, we detected P, LP, or VUS
in 93% of all genotyped PPCM patients with cancer. Of
those, 100% (10 of 10 patients) undergoing car-
diotoxic cancer therapy before PPCM carried at least 1
VUS or LP/P gene variant associated with DCM/HCM
and/or CPS/DDR, and one-half of them carried LP/P
CENTRAL ILLUSTRATION Potential Connections Among Cancer, Cancer Therapies, and the Genetic Predisposition
for Cardiomyopathy and Cancer in PPCM Patients
Pfeffer, T.J. et al. J Am Coll Cardiol CardioOnc. 2019;1(2):196–205.
DNA damage plays a central role in the development of cancer and also contributes to the development of heart failure. Mutations associated with cardiomyopathy
render the heart more sensitive to stress induced by cardiotoxic treatment and pregnancy. Therefore, patients with mutations associated with DDR have a significantly
elevated risk of developing cancer. Exposure to cardiotoxic cancer therapy, which either alone or in combination with mutations associated with DCM/HCM increases
the risk for developing PPCM. Furthermore, heart failure may promote early onset cancer in CPS mutation carriers and thereby can explain, at least in part, the higher
cancer risk in patients after PPCM. CPS ¼ cancer predisposition syndrome; DCM ¼ dilated cardiomyopathy; DDR ¼ DNA damage response; HCM ¼ hypertrophic
cardiomyopathy; PPCM ¼ peripartum cardiomyopathy.
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202variants. These observations suggest that genetic
predisposition for DCM/HCM and CPS may sensitize
to PPCM, especially in combination with previous
cardiotoxic cancer therapy.
Among the mutated genes associated with DCM/
HCM were TTN and MYH7 variants, which had pre-
viously been associated with PPCM (32). Additional
mutations were discovered in CPT2 and DSP. CPT2
deficiency impairs long-chain fatty-acid oxidation
leading to liver failure with hypoketotic hypoglyce-
mia, cardiomyopathy, seizures, and early death as
severe forms, and exercise-induced muscle pain and
weakness, sometimes associated with myoglobinuria
in milder forms (33). Heterozygotes are usually
asymptomatic, but manifesting heterozygous car-
riers have also been reported (33). DSP is an
important component of desmosomes, which are
dynamic junctions between cells that maintain the
structural integrity of skin and heart tissues by
withstanding shear forces (34). In the present study,we found cardiomyopathy-associated LP/P gene
variants also in a PPCM patient without cancer (a P
variant in the FKRP gene leading to Emery Dreyfuss
muscular dystrophy which is known to also affect
the heart) (23) with a similar frequency (approxi-
mately 15%) as reported in other PPCM collectives
(32). Whereas there was a tendency for such muta-
tions to be present in PPCM with cancer, this should
be addressed in larger PPCM collectives in the
future.
All PPCM patients with cancer were diagnosed
before the age of 49 years, and therefore are classi-
fied as early-onset cancer, which is more likely to be
associated with CPS, especially when mutations in
DDR genes can be identified (35–37). One-half of the
sequenced PPCM patients with cancer carried gene
variants associated with CPS (19,38,39), a finding that
had not been documented in PPCM patients. All CPS-
associated gene variants discovered in PPCM patients
with cancer mapped to genes involved in the DDR,
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203that is, in ATM, BRCA1, ERCC5, FANCA, NBN, POLD1,
RECQL4, and SLX4 (18–22) with LP/P variants in
either ATM, ERCC5, RECQL4, SLX4, and/or NBN.
Importantly, ATM, ERCC5, SLX4, and NBN variants
are associated with an increased risk for breast and/or
ovarian cancer (19,38–40). Both cancer forms were
present in one-third of the present PPCM cohort. The
patient with the compound heterozygous RECQL4
variants had a reported body height of only 154 cm
and was diagnosed with osteosarcoma, with a likely
diagnosis of a very rare, RECQL4-associated CPS
(RAPADILINO syndrome [OMIM-P: 266280],
Rothmund-Thomson syndrome [OMIM-P: 268400]).
Unfortunately, this patient was lost to follow-up, so
further symptoms of RECQL4-associated CPS (skin
changes, and skeletal abnormalities) could not be
evaluated. In contrast to the PPCM patients with
cancer, none of the 6 sequenced PPCM patients
without cancer carried DDR-associated gene variants
suggesting that the exclusive presence of mutations
in DDR genes in PPCM patients with cancer
(acknowledging small numbers in each group) might
indicate a connection between DDR gene variants,
PPCM, and cancer. Along this line, gene variants
associated with impaired DDR may affect the stress
tolerance and repairability of the heart, a notion
supported by the observation that mutations in ATM
and BRCA1 not only increase the risk for cancer, but
may also promote cardiomyopathies and heart failure
(41–43). In addition, BRCA mutation carriers dis-
played an increased risk for anthracycline-induced
cardiotoxicity (41). Alternatively, DDR mutations
may lead to a better efficacy of chemotherapy, as, for
example, cancer patients with systemic loss of func-
tion mutations in DDR genes have a better survival
rate after platinum-based chemotherapy (44).
Thereby, DDR mutations may allow patients with
childhood cancer to be healed from cancer but may
also increase the risk for a subsequent PPCM. Addi-
tional studies and longer follow-up data will be
required to analyze the impact of DDR mutations
with respect to PPCM complicated by cancer. In this
regard, comparison of whole-exome sequencing data
of childhood cancer survivors with and without sub-
sequent PPCM could provide insights whether the
prevalence of DDR associated mutations in PPCM
may predispose only for early-onset cancer or for
both diseases.
Our findings showing a high prevalence of CPS-
associated gene variants are also interesting in light
of a hypothesis put forward by a previous study
which suggested that heart failure might promote amalignant transformation of pretumor stages and the
progression of tumor disease (7). A possible expla-
nation is that PPCM patients with cancer after PPCM
had an existing genetic risk for early-onset cancer,
and heart failure in PPCM may have induced cancer.
We also observed that common PPCM risk factors
such as pre-eclampsia are less frequent in PPCM pa-
tients with cancer, supporting the hypothesis that
cancer-associated risk factors, such as cardiotoxic
cancer therapies and/or genetic predisposition, are
causally linked with PPCM and represent a subset of
PPCM different than that triggered by hypertensive
disorders of pregnancy.
STUDY LIMITATIONS. In addition to the limited
sample size, the follow-up data (average age at diag-
nosis: 34 years) available in this study ranged be-
tween 5 months and 19 years after PPCM diagnosis,
with an average of 33 months follow-up. It is possible
that the risk for cancer in PPCM patients is under-
estimated in this study and is increased for a wider
subset than that observed in our cohorts.CONCLUSIONS
This study is the first to describe a markedly
increased risk for malignancies both before and after
the diagnosis of PPCM. The type of cancer, the cancer
therapy, and/or gene variants associated with DCM/
HCM and/or with CPS/DDR may connect PPCM and
cancer. Therefore, pre-pregnancy echocardiographic
screening and counseling, together with close moni-
toring during pregnancy and postpartum, may be
recommended for patients with a history of cancer
and cancer therapy before pregnancy. In addition, as
PPCM patients may have a higher (genetic) risk of
developing cancer, they may require both regular
cardiovascular and cancer screening as well as
genetic screening for both diseases. In the future,
questionnaires for medical history for cancer disease
and whole-exome sequencing should be performed
in large registries such as the EURObservational
Research Program (45) or the investigations of
pregnancy-associated cardiomyopathy registry
(NCT01085955) (46) to confirm and further define the
connection between PPCM and cancer risk.
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Hannover, Germany. E-mail: hilfiker.denise@
mh-hannover.de. Twitter: @pfeffer_tj.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The pre-
sent study highlights a high cancer prevalence in PPCM
patients which is associated with CPS/DDR and/or DCM/
HCM gene variants. These observations suggest that ge-
netic screening for cancer and cardiomyopathy may be
advisable for PPCM patients. In addition, the study indi-
cates a higher risk of PPCM in cancer patients with
exposure to potentially cardiotoxic cancer therapies, even
in the absence of short-term clinical cardiotoxicity. Our
findings suggest cancer patients should undergo pre-
pregnancy echocardiographic screening and counseling,
as well as close monitoring during pregnancy and in the
first months postpartum. Furthermore, PPCM patients
should undergo not only cardiovascular monitoring, but
also regular cancer screening.
TRANSLATIONAL OUTLOOK: Further research in larger
independent PPCM cohorts is needed to confirm both the
higher prevalence of cancer in PPCM patients as well as the
higher risk for PPCM as a late form of cardiotoxicity after
cancer treatment. Moreover, experimental studies are
needed to determine the potential pathologic impact of
systemic DNA damage mutations (CPS/DDR) not only for
cancer but also for the development of PPCM. It is important
to understand whether DCM/HCM mutations leading to
PPCMmay also promote the early-onset cancer after PPCM.
Pfeffer et al. J A C C : C A R D I O O N C O L O G Y , V O L . 1 , N O . 2 , 2 0 1 9
Increased Cancer Prevalence in PPCM D E C E M B E R 2 0 1 9 : 1 9 6 – 2 0 5
204RE F E RENCE S1. Hilfiker-Kleiner D, Haghikia A, Nonhoff J,
Bauersachs J. Peripartum cardiomyopathy: current
management and future perspectives. Eur Heart J
2015;36:1090–7.
2. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al.
Current state of knowledge on aetiology, diag-
nosis, management, and therapy of peripartum
cardiomyopathy: a position statement from the
Heart Failure Association of the European Soci-
ety of Cardiology Working Group on peripartum
cardiomyopathy. Eur J Heart Fail 2010;12:
767–78.
3. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and
epidemiology of peripartum cardiomyopathy. Nat
Rev Cardiol 2014;11:364–70.
4. Liu S, Aghel N, Belford L, et al. Cardiac out-
comes in pregnant women with treated cancer.
J Am Coll Cardiol 2018;72:2087–9.
5. Katz A, Goldenberg I, Maoz C, Thaler M,
Grossman E, Rosenthal T. Peripartum cardiomy-
opathy occurring in a patient previously treated
with doxorubicin. Am J Med Sci 1997;314:
399–400.
6. Haghikia A, Podewski E, Libhaber E, et al.
Phenotyping and outcome on contemporary
management in a German cohort of patients with
peripartum cardiomyopathy. Basic Res Cardiol
2013;108:366.
7. Meijers WC, Maglione M, Bakker SJL, et al. The
failing heart stimulates tumor growth by circu-
lating factors. Circulation 2018;138:678–91.
8. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al.
Current management of patients with severe acute
peripartum cardiomyopathy: practical guidance
from the Heart Failure Association of the European
Society of Cardiology Study Group on peripartum
cardiomyopathy. Eur J Heart Fail 2016;18:
1096–105.
9. Bauersachs J, Koenig T. Devil in disguise: hints
and pitfalls in diagnosis of peripartum cardiomy-
opathy. Circ Heart Fail 2018;11:e004620.10. Halkein J, Tabruyn SP, Ricke-Hoch M, et al.
MicroRNA-146a is a therapeutic target and
biomarker for peripartum cardiomyopathy. J Clin
Invest 2013;123:2143–54.
11. Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al.
Long-term prognosis, subsequent pregnancy,
contraception and overall management of peri-
partum cardiomyopathy: practical guidance pa-
per from the Heart Failure Association of the
European Society of Cardiology Study Group on
Peripartum Cardiomyopathy. Eur J Heart Fail
2018;20:951–62.
12. Bertz JD, Haberland S, Kraywinkel J, Kurth BM,
Wolf U. Verbreitung von Krebserkrankungen in
Deutschland - Entwicklung der Prävalenzen zwi-
schen 1990 und 2010. Berlin, Germany: Robert
Koch-Institut, 2010.
13. Thorvaldsdottir H, Robinson JT,
Mesirov JP. Integrative Genomics Viewer
(IGV): high-performance genomics data visu-
alization and exploration. Brief Bioinform
2013;14:178–92.
14. Richards S, Aziz N, Bale S, et al. Standards and
guidelines for the interpretation of sequence var-
iants: a joint consensus recommendation of the
American College of Medical Genetics and Geno-
mics and the Association for Molecular Pathology.
Genet Med 2015;17:405–24.
15. Kohler S, Carmody L, Vasilevsky N, et al.
Expansion of the Human Phenotype Ontology
(HPO) knowledge base and resources. Nucleic
Acids Res 2019;47:D1018–27.
16. Whitworth J, Smith PS, Martin JE, et al.
Comprehensive cancer-predisposition gene testing
in an adult multiple primary tumor series shows a
broad range of deleterious variants and atypical
tumor phenotypes. Am J Hum Genet 2018;103:
3–18.
17. Lek M, Karczewski KJ, Minikel EV, et al. Anal-
ysis of protein-coding genetic variation in 60,706
humans. Nature 2016;536:285–91.18. Blackford AN, Jackson SP. ATM, ATR, and
DNA-PK: the trinity at the heart of the DNA
damage response. Mol Cell 2017;66:801–17.
19. Knijnenburg TA, Wang L, Zimmermann MT,
et al. Genomic and molecular landscape of DNA
damage repair deficiency across The Cancer
Genome Atlas. Cell Rep 2018;23:239–254 e6.
20. Nicolas E, Golemis EA, Arora S. POLD1: central
mediator of DNA replication and repair, and
implication in cancer and other pathologies. Gene
2016;590:128–41.
21. Rother MB, van Attikum H. DNA repair goes
hip-hop: SMARCA and CHD chromatin remodellers
join the break dance. Philos Trans R Soc Lond B
Biol Sci 2017:372.
22. Yoshioka J. Thioredoxin reductase 2 (Txnrd2)
regulates mitochondrial integrity in the progres-
sion of age-related heart failure. J Am Heart Assoc
2015;4:e002278.
23. Schottlaender LV, Petzold A, Wood N,
Houlden H. Diagnostic clues and manifesting car-
riers in fukutin-related protein (FKRP) limb-girdle
muscular dystrophy. J Neurol Sci 2015;348:266–8.
24. El-Amraoui A, Petit C. Cadherins as targets for
genetic diseases. Cold Spring Harb Perspect Biol
2010;2:a003095.
25. Husby A, Wohlfahrt J, Oyen N, Melbye M.
Pregnancy duration and breast cancer risk. Nature
Commun 2018;9:4255.
26. Nichols HB, Schoemaker MJ, Cai J, et al. Breast
cancer risk after recent childbirth: a pooled anal-
ysis of 15 prospective studies. Ann Intern Med
2019;170:22–30.
27. Ameri P, Canepa M, Anker MS, et al. Cancer
diagnosis in patients with heart failure: epidemi-
ology, clinical implications and gaps in knowledge.
Eur J Heart Fail 2018;20:879–87.
28. Shelburne N, Adhikari B, Brell J, et al. Cancer
treatment-related cardiotoxicity: current state of
knowledge and future research priorities. J Natl
Cancer Inst 2014;106:pii:dju232.
J A C C : C A R D I O O N C O L O G Y , V O L . 1 , N O . 2 , 2 0 1 9 Pfeffer et al.
D E C E M B E R 2 0 1 9 : 1 9 6 – 2 0 5 Increased Cancer Prevalence in PPCM
20529. Zamorano JL, Lancellotti P, Rodriguez
Munoz D, et al. 2016 ESC position paper on cancer
treatments and cardiovascular toxicity developed
under the auspices of the ESC Committee for
Practice Guidelines: the task force for cancer
treatments and cardiovascular toxicity of the Eu-
ropean Society of Cardiology (ESC). Eur Heart J
2016;37:2768–801.
30. Hilfiker-Kleiner D, Ardehali H, Fischmeister R,
Burridge P, Hirsch E, Lyon AR. Late onset heart
failure after childhood chemotherapy. Eur Heart J
2019;40:798–800.
31. Garcia-Pavia P, Kim Y, Alejandra Restrepo-
Cordoba M, et al. Genetic variants associated with
cancer therapy-induced cardiomyopathy. Circula-
tion 2019;140:31–41.
32. Ware JS, Li J, Mazaika E, et al. Shared genetic
predisposition in peripartum and dilated cardio-
myopathies. N Engl J Med 2016;374:233–41.
33. Wieser T. Carnitine Palmitoyltransferase II
Deficiency. In: Adam MP, Ardinger HH, Pagon RA,
et al (eds). Seattle, WA: GeneReviews; 1993.
34. Al-Jassar C, Bikker H, Overduin M, Chidgey M.
Mechanistic basis of desmosome-targeted dis-
eases. J Mol Biol 2013;425:4006–22.
35. Fortuno C, James PA, Spurdle AB. Current re-
view of TP53 pathogenic germline variants in
breast cancer patients outside Li-Fraumeni syn-
drome. Hum Mutat 2018;39:1764–73.36. Mahdavi M, Nassiri M, Kooshyar MM, et al.
Hereditary breast cancer; genetic penetrance and
current status with BRCA. J Cell Physiol 2019;234:
5741–50.
37. McReynolds LJ, Savage SA. Pediatric leukemia
susceptibility disorders: manifestations and man-
agement. Hematol Am Soc Hematol Educ Program
2017;2017:242–50.
38. Berardinelli F, di Masi A, Antoccia A. NBN gene
polymorphisms and cancer susceptibility: a sys-
temic review. Curr Genomics 2013;14:425–40.
39. Kobayashi H, Ohno S, Sasaki Y, Matsuura M.
Hereditary breast and ovarian cancer susceptibility
genes (review). Oncol Rep 2013;30:1019–29.
40. Bonache S, Esteban I, Moles-Fernandez A,
et al. Multigene panel testing beyond BRCA1/2 in
breast/ovarian cancer Spanish families and clinical
actionability of findings. J Cancer Res Clin Oncol
2018;144:2495–513.
41. Sajjad M, Fradley M, Sun W, et al. An explor-
atory study to determine whether BRCA1 and
BRCA2 mutation carriers have higher risk of car-
diac toxicity. Genes (Basel) 2017;8:pii:E59.
42. Shukla PC, Singh KK, Quan A, et al. BRCA1 is an
essential regulator of heart function and survival
following myocardial infarction. Nat Commun
2011;2:593.
43. Nakada Y, Nhi Nguyen NU, Xiao F, et al.
DNA damage response mediates pressureoverload-induced cardiomyocyte hypertrophy.
Circulation 2019;139:1237–9.
44. Hassan R, Morrow B, Thomas A, et al.
Inherited predisposition to malignant mesothe-
lioma and overall survival following platinum
chemotherapy. Proc Natl Acad Sci U S A 2019;
116:9008–13.
45. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al.
Clinical characteristics of patients from the
worldwide registry on peripartum cardiomyopa-
thy (PPCM): EURObservational Research Pro-
gramme in conjunction with the Heart Failure
Association of the European Society of Cardiol-
ogy Study Group on PPCM. Eur J Heart Fail 2017;
19:1131–41.
46. McNamara DM, Elkayam U, Alharethi R,
et al. Clinical outcomes for peripartum cardio-
myopathy in North America: results of the IPAC
study (Investigations of Pregnancy-Associated
Cardiomyopathy). J Am Coll Cardiol 2015;66:
905–14.KEY WORDS cancer, cardiotoxicity,
genetics, peripartum cardiomyopathy,
whole-exome sequencingAPPENDIX For supplemental tables, please
see the online version of this paper.
